Huons Co., Ltd. (KOSDAQ:243070)
27,750
-400 (-1.42%)
Dec 10, 2025, 3:30 PM KST
Huons Revenue
Huons had revenue of 153.72B KRW in the quarter ending September 30, 2025, with 4.66% growth. This brings the company's revenue in the last twelve months to 602.21B, up 2.27% year-over-year. In the year 2024, Huons had annual revenue of 590.23B with 6.92% growth.
Revenue (ttm)
602.21B
Revenue Growth
+2.27%
P/S Ratio
0.54
Revenue / Employee
660.31M
Employees
912
Market Cap
323.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.23B | 38.22B | 6.92% |
| Dec 31, 2023 | 552.01B | 59.62B | 12.11% |
| Dec 31, 2022 | 492.39B | 55.48B | 12.70% |
| Dec 31, 2021 | 436.91B | 30.23B | 7.43% |
| Dec 31, 2020 | 406.68B | 41.66B | 11.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |